Welcome to our dedicated page for Phathom Pharmaceuticals SEC filings (Ticker: PHAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phathom Pharmaceuticals, Inc. filings document financial reporting, governance, capital structure and product-development disclosures for a Nasdaq-listed biopharmaceutical company focused on gastrointestinal diseases. Form 8-K reports include quarterly and annual results, preliminary financial information, material agreements, financing-related updates, and other event disclosures tied to VOQUEZNA® commercialization and clinical development.
Proxy materials cover board matters, executive compensation, equity awards and shareholder voting items. The filing record also describes registered common stock, risk-oriented forward-looking statements, and clinical or publication updates involving VOQUEZNA in GERD, non-erosive reflux disease and eosinophilic esophagitis.
Anne Marie Cook has filed an initial Form 3 Statement of Beneficial Ownership following her appointment as Chief Legal Officer & Corporate Secretary at Phathom Pharmaceuticals (PHAT). The filing, dated June 28, 2025, discloses her beneficial ownership status as of June 23, 2025.
Key details of the filing:
- Cook currently owns no securities of Phathom Pharmaceuticals
- No derivative securities (options, warrants, etc.) are reported as beneficially owned
- The filing is made as an individual submission, not as part of a group
- Direct ownership form is indicated for the zero securities position
This Form 3 filing is a standard regulatory requirement for new officers, directors, and 10% shareholders under Section 16(a) of the Securities Exchange Act of 1934, establishing a baseline for future transaction reporting.